(ORDO NEWS) — Moderna, an American biotechnology firm, has reported “positive interim” results from the first clinical trials of its current pandemic vaccine, SARS-CoV-2. As follows from the published data, so far the check has passed on a small sample – 45 volunteers.
The mRNA-1273 vaccine, tested on these people, was able to elicit an equally active immune response as people recovering from Covid-19, the company said. So far, these are eight people: the full test results of the first phase of the vaccine being developed are still being processed. It is known that three groups of 15 patients each received three different doses of the vaccine.
According to the company, the vaccine “was generally safe and well-tolerated,” although, as noted by the project’s chief medical researcher, Dr. Tal Sachs, given the early stage of clinical trials, it is too early to draw final conclusions.
It is worth noting that clinical trials were conducted under the auspices of the US Department of Health – National Institutes of Health. The government has invested half a billion dollars in the development of a vaccine by Moderna.
The second phase of the tests, which will be attended by more vaccinated volunteers, will begin in the near future, company representatives said. The third test phase, the last and most important to confirm the effectiveness of the drug, should start in July.
Earlier in the preclinical phase, which was conducted on model animals, it turned out that the vaccine prevented the multiplication of the virus in the lungs of mice, which made it possible to proceed to the stage of clinical trials. If the second and third phases are successful, the drug may be one of the first on the market. Today, several different countries have come close to the crucial stages of testing coronavirus vaccines.
Contact us: [email protected]